Lupin Ltd.

Financial

	Lupin	Mankind Pharma	Cipla
Operational Metrics
API Sector
US DMF Filings	157.0 .	n/a	1704.0 .
Pharmaceutical Sector
Number of ANDA's Filed in USA	431.0 .	55.0 .	277.0 .
Number of ANDA's Approved By USFDA	314.0 .	32.0 .	196.0 .
Domestic Sales Growth - YoY	8.1 %	n/a	9.1 %
R&D as a % of Total Sales	8.7 %	2.15 %	7.2 %
Financials
5 yr Average ROE	0.39 %	23.48 %	11.43 %
5yr average Equity Multiplier	1.85	1.4	1.39
5yr Average Asset Turnover Ratio	0.66	1.02	0.76
5yr Avg Net Profit Margin	0.74 %	16.52 %	10.96 %
Price to Book	5.17	9.11	4.48
P/E	38.61	44.58	29.0
5yr Avg Cash Conversion Cycle	-27.27 Days	-45.92 Days	-3.69 Days
Inventory Days	51.43 Days	60.23 Days	59.85 Days
Days Receivable	56.09 Days	19.33 Days	44.13 Days
Days Payable	155.83 Days	132.42 Days	114.64 Days
5yr Average Interest Coverage Ratio	3.33	47.23	23.71
5yr Avg ROCE	6.39 %	31.06 %	15.24 %
5yr Avg Operating Profit Margin	13.98 %	25.32 %	22.51 %
5 yr average Debt to Equity	0.43	0.07	0.13
5yr CAGR Net Profit	-6.65 %	17.25 %	12.9 %
5yr Average Return on Assets	0.23 %	16.73 %	8.36 %
Shareholdings
Promoter Holding	47.01 %	74.88 %	33.47 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.15 %	-1.62 %	-3.26 %
Change in Mutual Fund Holding (3 Yrs)	3.77 %	6.74 %	2.19 %

Business

	Lupin	Mankind Pharma	Cipla
Product Wise Break-Up	Product Wise Break-Up Advanced Markets Formulations 45.0 India 34.0 Emerging Market 12.0 Active Pharmaceutical Ingredient (API) 9.0 NCD 1.0 USA 0 Developed Markets 0 Generic FDF 0 Custom Synthesis 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 New ventures 0 Pharmaceuticals 0	Product Wise Break-Up Gynaecology 8.0 Generic FDF 0 Respiratory 9.0 Advanced Markets Formulations 0 Developed Markets 0 Dermatology 5.0 Emerging Market 0 Gastrointestinal 10.0 Cardiovascular 15.0 Anti-infectives 15.0 Active Pharmaceutical Ingredient (API) 0 Neuro/CNS 3.0 New ventures 0 VMN 9.0 Urology 6.0 Anti-Diabetic 8.0 Pharmaceuticals 0 Pain/Analgesics 4.0 USA 0 NCD 0 Custom Synthesis 0 India 0 Others 8.0	Product Wise Break-Up Gynaecology 0 Generic FDF 0 Respiratory 0 Advanced Markets Formulations 0 Developed Markets 0 Dermatology 0 Emerging Market 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 Active Pharmaceutical Ingredient (API) 0 Neuro/CNS 0 New ventures 3.43 VMN 0 Urology 0 Anti-Diabetic 0 Pharmaceutical 96.57 Pain/Analgesics 0 USA 0 NCD 0 Custom Synthesis 0 India 0
Segment Break-Up	Segment Break-Up Pharmaceuticals 100.0 Research Services & Sale of IP`s 0	-	-
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti - Diabetes 21.0 Cardiac Science 21.0 Respiratory Systems 15.0 Gastro Intestinal 9.0 Anti-Infective 7.0 Gynecology 5.0 Central Nervous System (CNS) 5.0 Vitamins / Minerals / Nutrients 5.0 Pain Management 4.0 Anti-Tuberculosis 3.0 Anti-infectives 0 Urology 0 Gastro Intestinal 0 Antivirals 0 Derma 0 Pain / Analgesics 0 Neuro /CNS 0 Gynaec. 0 Vitamins 0 Antineoplast 0 Opthal/Otologicals 0 Oncology 0 Anti Diabetic 0 Others 5.0	-	Therapeutic Area Wise Break-Up - Domestic Derma 2.7 Oncology 0 Antineoplast 0 Vitamins / Minerals / Nutrients 0 Pain Management 0 Anti-Infective 0 Respiratory Systems 0 Ophthalmology 3.1 Anti-Infective 15.3 Anti - Diabetes 0 Urology 4.8 Gastro Intestinal 5.8 Central Nervous System (CNS) 0 Anti-Tuberculosis 0 Central Nervous System (CNS) 2.3 Cardiac Science 0 Vitamins 0 Anti - Diabetes 3.8 Antivirals 3.1 Gynaec. 0 Gynecology 0 Pain Management 3.5 Others 55.6
Location Wise Break-Up	Location Wise Break-Up USA 39.0 India 33.0 EMEA 11.0 Developed Markets 10.0 API 5.0 Japan 0 Nepal 0 Sri Lanka 0 Bangladesh 0 SAGA 0 Europe 0 Global API 0 Rest of the World 0 Emerging Markets 0 North America 0 Others 2.0	Location Wise Break-Up North America 0 API 0 EMEA 0 SAGA 0 Bangladesh 0 USA 0 Sri Lanka 0 Japan 0 Rest of the World 0 Europe 0 Global API 0 India 89.0 Nepal 0 Emerging Markets 0 Developed Markets 0 Others 11.0	Location Wise Break-Up North America 29.0 API 0 EMEA 0 SAGA 12.0 Bangladesh 0 USA 0 Sri Lanka 0 Japan 0 Rest of the World 11.0 Europe 0 Global API 2.0 India 44.0 Nepal 0 Emerging Markets 0 Developed Markets 0 Others 2.0
Acute vs Chronic	Acute vs Chronic Chronic 62.5 Acute 37.5	Acute vs Chronic Acute 63.0 Chronic 37.0	-

Lupin Ltd.

SIGN UP FOR FREE